22nd Century Group, Inc. and GVB Biopharma have entered into an agreement with Cannabinoid API Solutions (CAS) and Transo-Pharm for global sales, marketing and distribution of GVB's Cannabinoid APIs. With more than 35 years of industry experience as a leading global supplier of pharmaceutical grade APIs, Transo-Pharm is a well-established supplier and distributor of pharmaceutical APIs to a broad portfolio of branded and generic finished drug product manufacturers, including more than 75 current active ongoing development programs. Transo-Pharm is partnered with an extensive range of reputable multinational pharmaceutical companies, all of which will have immediate access to GVB's cannabinoid APIs.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.829 USD | -4.16% | +23.93% | -72.17% |
30/05 | 22nd Century Group, Inc. Announces Resignation of John Miller as August 2, 2024 | CI |
15/05 | Transcript : 22nd Century Group, Inc., Q1 2024 Earnings Call, May 15, 2024 |
1st Jan change | Capi. | |
---|---|---|
-72.17% | 68.74L | |
+18.29% | 8.2TCr | |
+0.75% | 6.93TCr | |
+20.00% | 4.91TCr | |
+0.12% | 710.17Cr | |
-20.11% | 514.11Cr | |
-11.50% | 225.07Cr | |
-16.48% | 201.9Cr | |
-35.28% | 154Cr | |
-12.27% | 115.86Cr |
- Stock Market
- Equities
- XXII Stock
- News 22nd Century Group, Inc.
- 22Nd Century Group Announces New Global Sales, Marketing and Distribution Agreement with Transo-Pharm for Cannabinoid APIs